Eli Lilly & Co.

Eli Lilly and Company is engaged in discovering, developing, manufacturing, and marketing products in two business segments: human pharmaceutical products; and animal health products. The company's human pharmaceutical products include: cardiovascular, endocrinology, immunology, neuroscience and oncology products. The company's animal health products are comprised of products for animals, among others, which include Clynav?, a vaccine to control pancreas disease in salmon; Coban?, Maxiban?, and Monteban?, anticoccidial agents for use in poultry; as well as products for companion animals, which include Comfortis?, a chewable tablet that kills fleas and prevents flea infestations on dogs.
  • TickerLLY
  • ISINUS5324571083
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

With a more favourable environment, ELI LILLY & CO. improves to Positive

ELI LILLY & CO. (US), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date July 3, 2020, the closing price was USD 163.87 and its potential was estimated at USD 180.85.

Valens Research

Valens Equity Insights and Inflections - 2020 06 30

ADS currently trades at a historical low relative to Uniform earnings, with a 6.2x Uniform P/E (Fwd V/E′). At these levels, the market is pricing in expectations for Uniform ROA to decline from 61% in 2019 to a 17% trough in 2024, accompanied by 8% Uniform asset shrinkage going forward. Meanwhile, analysts have less bearish expectations, projecting Uniform ROA to fall to 35% in 2020, driven by coronavirus headwinds, before recovering to 50% in 2021, accompanied by 13% Uniform asset shrinkage. Moreover, management is confident about customer payments, their liquidity, and their ability to pay t...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Valens Research

LLY - Embedded Expectations Analysis - 2020 06 25

Eli Lilly and Company (LLY:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 26.8x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may be concerned about their sales guidance, the impact of coronavirus, and their innovation pipeline Specifically, management may lack confidence in their ability to control operating expenses, sustain revenue growth from stockpiling, and meet their EPS guidance. In addition, they may be concerned about continued new patient start declines in China and the impact of inc...

Eli Lilly & Co: 1 director sold

A director at Eli Lilly & Co sold 17,000 shares at 162.941USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold and...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold and...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Getting Long-Term Oversold Note: We have suspended the Russell grids and Sector comments this week due to heightened volatility. Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward. Clues that a breakdown was increasingly likely started coming as early as Thursday, when the KBW Bank index broke below key $89 support we outlined last week. Friday's widening move in h...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Eli Lilly & Co: 1 director sold

A director at Eli Lilly & Co sold 17,000 shares at 162.941USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Valens Research

Valens Equity Insights and Inflections - 2020 06 30

ADS currently trades at a historical low relative to Uniform earnings, with a 6.2x Uniform P/E (Fwd V/E′). At these levels, the market is pricing in expectations for Uniform ROA to decline from 61% in 2019 to a 17% trough in 2024, accompanied by 8% Uniform asset shrinkage going forward. Meanwhile, analysts have less bearish expectations, projecting Uniform ROA to fall to 35% in 2020, driven by coronavirus headwinds, before recovering to 50% in 2021, accompanied by 13% Uniform asset shrinkage. Moreover, management is confident about customer payments, their liquidity, and their ability to pay t...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Valens Research

LLY - Embedded Expectations Analysis - 2020 06 25

Eli Lilly and Company (LLY:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 26.8x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may be concerned about their sales guidance, the impact of coronavirus, and their innovation pipeline Specifically, management may lack confidence in their ability to control operating expenses, sustain revenue growth from stockpiling, and meet their EPS guidance. In addition, they may be concerned about continued new patient start declines in China and the impact of inc...

Franc Gregori ...
  • Lala Gregorek
  • Mick Cooper

Trinity Delta Lighthouse: Hutchison China MediTech

Trinity Delta view: Inclusion of fruquintinib in the China NRDL is an important milestone for Chi-Med. It is its first novel oncology drug commercially launched in China and securing NRDL reimbursement will significantly boost market penetration in 3L CRC. NRDL listing is associated with a c64% gross (we estimate 34% net) price discount; however, this is likely to be more than offset by higher volumes, driving both manufacturing revenue and royalties from sales growth. Elunate is currently Chi-Med’s most valuable asset, contributing $9.47/ADS or £1.46/share to our company valuation. We foreca...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior